ADC Therapeutics Reports Q1 2025 Financial Results

ADC Therapeutics Ltd ( (ADCT) ) has released its Q1 earnings. Here is a breakdown of the information ADC Therapeutics Ltd presented to its investors.

ADC Therapeutics Ltd, a commercial-stage global leader in the field of antibody drug conjugates (ADCs), is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

In the first quarter of 2025, ADC Therapeutics reported financial results and operational updates, highlighting the acceptance of their LOTIS-7 abstract for presentation at major conferences and the promising data from ZYNLONTA® plus glofitamab trials. The company also reached a milestone in patient enrollment for their LOTIS-7 trial and expects to provide further updates in the latter half of the year.

Key financial metrics for the quarter include net product revenues of $17.4 million, a slight decrease from the previous year, while license revenues and royalties saw a significant increase to $5.6 million. The company reported a net loss of $38.6 million, an improvement from the previous year’s loss, attributed to higher license revenues and reduced operating expenses. Cash and cash equivalents stood at $194.7 million, with a cash runway expected to extend into the second half of 2026.

Operational highlights include the discontinuation of the ADCT-602 trial and progress in other preclinical programs. The company is focused on expanding the potential of ZYNLONTA in combination therapies and earlier lines of treatment, with ongoing trials and presentations at international conferences.

Looking ahead, ADC Therapeutics remains optimistic about its strategic direction and the potential of its ADC technology. The management is confident in the progress of its clinical trials and the opportunities for ZYNLONTA in the treatment of diffuse large B-cell lymphoma and other malignancies.